Investment Q&A

Q: Can you comment on the latest deal by this company and its prospects go forward? Would you consider it a buy, sell or hold? Thanks

Q: Would you think that Amazon's announcement yesterday about venturing back into the drug prescription business is affecting the performance of NBLY?

Q: Hi

I noticed that you are recommending Lily for US healthcare. Are you still high on Abbvie?

Carl

Q: PNT Point Bio. Peter; How long does the new prostrate trial take and,if successful would it better to own it or LNTH? Thanks
Rod

Q: your thoughts on the recent announcement and its impact - sell, buy or hold

Q: I bought IHI in early 2021 in the belief that there was a big backlog of surgeries during the pandemic. Do you know if that backlog still exists?
Thank you.

Q: your thoughts on Sanara MedTech
thanks again

Q: Peter; Could you updates your thoughts on BLUE ? Thanks
Rod

Q: I own both these stocks. I am even on Quis but have a loss on RHT. If you were to own one of these which would it be? I was thinking of selling the RHT and adding to my Quis position.

Q: On jan 17 you indicated the recent stock move was a bit "suspicious." Can you expand and explain what you mean by this. Thanks John

Q: Moving past the opioid settlement, is this name worth revisiting? I have not owned in years, debt appears better but still high. Is there a better play on pharmaceuticals for an aging population.

Q: What do you think the odds are of an equity raise in the near future?

Q: What is your take on this NARA
Thanks Gang

Q: Your advices to hold on to the above stocks for January bounce is correct so far. When will the bounce normally ends? When it ends,is it time to sell OR should ask the question then? Well had a huge increase of 15 94% to $3.71 today.Please comment as I cannot find any news. Thanks for U usual great services & views

Q: Do you have any updated information on this stock and what are your views on it.

Q: The market seems to like the news but I would appreciate your views on their just released Q1 results. I realize that they still came in at a loss but that was solely attributable to an increase in operating costs (specifically R&D and a ramp up of its US sales force in advance of the release of SavvyWire). I remain surprised that we're still trading below their recent financing level. Thanks as always.

Q: I am currently down about 60% on WELL Health
- I am considering buying more to average down on my cost

Your thoughts?

Thanks,
M

Q: Your analysis of AXSM.US would be appreciated. Any news on the reasons for the large drop.

Thanks

Thomas

Q: Why the big drop in price today?

Q: We often see conflicting analyst opinions, but ratings of MDT seem to be on one extreme or other. For what it’s worth, MDT appears on various lists of “best stocks for 2023”. And just this week, Barrons carried this story: “ Buy Medtronic Stock. Shares of the Dividend Aristocrat Look Attractive” (January 2). This morning RBC-DI downgraded MDT from outperform while CFRA maintains a Buy. Both RBC-DI and CFRA seem to reasonably good track records. I have held MDT shares from multi-year highs all the way down to today’s miserable level. (Tax loss not useable).

I have previously asked you about MDT and possibly others here may have done so too. Would you care to take a side in this frustrating debate with your reasons? Thanks.